Source: Annual Congress 2012 - Novel approaches to lung transplantation



Rating:

Share or cite this content

Citations should be made in the following way:
A. Simon, A. Glanville, M. Zamora, T. Hodges, S. Arcasoy, M. Musk, U. Sommerwerck, J. DeVincenzo, V. Karsten, S. Shah, J. Cehelsky, S. Nochur, J. Gollob, A. Vaishnaw, J. Gottlieb (Cambridge, Aurora, Phoenix, New York, Memphis, United States Of America; Darlinghurst, Perth, Australia; Essen, Hanover, Germany). Results of a phase 2b multi-center, randomized, double-blind, placebo-controlled study of an RNAi therapeutic, ALN-RSV01, in respiratory syncytial virus (RSV)-infected lung transplant patients. Eur Respir J 2012; 40: Suppl. 56, 1858

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of recombinant human deoxyribonuclease (Rh-DNase) in infants hospitalised with respiratory syncytial virus bronchiolitis: a multicentre randomised double-blind clinical trial Source: Eur Respir J 2006; 28: Suppl. 50, 758s Year: 2006 Effectiveness of influenza vaccination in asthmatic children: randomised, double-blind, placebo-controlled trial Source: Eur Respir J 2002; 20: Suppl. 38, 146s Year: 2002 RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations Source: Virtual Congress 2021 – ALERT: COPD Year: 2021 PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 A randomized, double-blind, placebo-controlled, phase III study of the safety and efficacy of interferon gamma-1b in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2007 - Clinical trial: new biological approaches to respiratory diseases Year: 2007 Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017 Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO) Source: ERJ Open Res, 8 (1) 00610-2021; 10.1183/23120541.00610-2021 Year: 2022 Chinese herbs in treatment of influenza: A multi-centre, randomized, double-blind, placebo-controlled trial Source: Annual Congress 2010 - New aspects of treatment of lower respiratory tract infections Year: 2010 Omalizumab efficacy following cat allergen exposure: Results from a randomized, double-blind, placebo-controlled, parallel-group study in patients with moderate asthma Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010 A randomized, controlled, open-label study to evaluate the efficacy and safety of oral lopinavir-ritonavir in adults hospitalized with COVID-19 virus infection Source: Virtual Congress 2020 – Chinese programme 2020: Part I Year: 2020 High-dose inhaled corticosteroids prevent wheeze following respiratory syncytial virus infection: a randomized double-blind placebo-controlled trial Source: Annual Congress 2008 - Paediatric respiratory epidemiology II: air pollution studies and infectious disease epidemiology Year: 2008 Acetazolamide administration following upper airway surgery for SDB. Preliminary results of a randomized, double-blind, placebo-controlled study Source: Eur Respir J 2005; 26: Suppl. 49, 201s Year: 2005 Recombinant human deoxyribonuclease (rhDNase) for the treatment of acute asthma in children: a multicentre randomised double-blind clinical trial Source: Annual Congress 2007 - Childhood asthma: treatment and follow-up Year: 2007 RCT Abstract - Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs Year: 2021 Methotrexate in treatment of severe difficult-to-treat asthma: randomized, double-blind, placebo-controlled study Source: Annual Congress 2007 - Towards controlling severe asthma Year: 2007 A randomized, double-blind, placebo-controlled study to evaluate the role of formoterol in management of acute asthma Source: Eur Respir J 2006; 28: Suppl. 50, 498s Year: 2006 Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial. Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018 A single-centre, placebo-controlled, double-blinded, randomized, cross-over study of Iloprost in patients with Eisenmenger syndrome Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Working memory training efficacy in COPD: the randomised, double-blind, placebo-controlled Cogtrain trial Source: ERJ Open Res, 7 (4) 00475-2021; 10.1183/23120541.00475-2021 Year: 2021